performed a study on 133 patients with RR CD19+ B cell malignancies who underwent CD19 CAR-T cell therapy, and demonstrated that serum VWF and Ang-2 concentrations were higher in patients with grade ≥4 CRS (21). The gene discussed is CD19; the disease is congenital rubella syndrome.